BridgeBio Pharma Inc (BBIO)
23.42
+0.18
(+0.77%)
USD |
NASDAQ |
Nov 22, 16:00
23.44
+0.02
(+0.09%)
After-Hours: 20:00
BridgeBio Pharma Cash from Financing (Quarterly): 0.707M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.707M |
| June 30, 2024 | -5.729M |
| March 31, 2024 | 279.55M |
| December 31, 2023 | -4.523M |
| September 30, 2023 | 307.04M |
| June 30, 2023 | -1.231M |
| March 31, 2023 | 150.25M |
| December 31, 2022 | 6.377M |
| September 30, 2022 | 1.445M |
| June 30, 2022 | -20.80M |
| March 31, 2022 | -0.16M |
| December 31, 2021 | 325.38M |
| September 30, 2021 | -135.46M |
| June 30, 2021 | -1.391M |
| Date | Value |
|---|---|
| March 31, 2021 | 547.91M |
| December 31, 2020 | 4.531M |
| September 30, 2020 | 2.782M |
| June 30, 2020 | 0.703M |
| March 31, 2020 | 439.17M |
| December 31, 2019 | 42.90M |
| September 30, 2019 | 367.51M |
| June 30, 2019 | -9.969M |
| March 31, 2019 | -1.651M |
| December 31, 2018 | 274.17M |
| September 30, 2018 | -1.727M |
| June 30, 2018 | 213.41M |
| March 31, 2018 | 15.69M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-135.46M
Minimum
Sep 2021
547.91M
Maximum
Mar 2021
96.97M
Average
2.114M
Median
Cash from Financing (Quarterly) Benchmarks
| Pfizer Inc | -4.636B |
| Alnylam Pharmaceuticals Inc | 102.76M |
| Vertex Pharmaceuticals Inc | -387.50M |
| PTC Therapeutics Inc | -17.63M |
| Bristol-Myers Squibb Co | -3.852B |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -180.57M |
| Cash from Investing (Quarterly) | 38.23M |
| Free Cash Flow | -456.32M |
| Free Cash Flow Per Share (Quarterly) | -0.967 |
| Free Cash Flow to Equity (Quarterly) | -184.02M |
| Free Cash Flow Yield | -10.69% |